SRR23303769
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.520
- INTERFERON_GAMMA_RESPONSE+0.410
- INFLAMMATORY_RESPONSE+0.280
- IL6_JAK_STAT3_SIGNALING+0.220
- PROTEIN_SECRETION+0.220
- TNFA_SIGNALING_VIA_NFKB+0.200
- COMPLEMENT+0.190
- CHOLESTEROL_HOMEOSTASIS+0.160
- ALLOGRAFT_REJECTION+0.120
- KRAS_SIGNALING_UP+0.120
Top 10 suppressed
- E2F_TARGETS-0.470
- MYC_TARGETS_V1-0.440
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.420
- MYC_TARGETS_V2-0.400
- OXIDATIVE_PHOSPHORYLATION-0.380
- DNA_REPAIR-0.350
- G2M_CHECKPOINT-0.330
- WNT_BETA_CATENIN_SIGNALING-0.330
- UV_RESPONSE_DN-0.320
- ANGIOGENESIS-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 3a2b80a5-6937-423a-92bf-9e25a0b23c5b | — | — | 0.831 |
| 2 | SRR25043624 | — | — | 0.821 |
| 3 | 94b2af92-0cfc-40b2-977d-6bd0fa4440d9 | — | — | 0.814 |
| 4 | DRR168517 | — | — | 0.810 |
| 5 | SRR2778078 | — | — | 0.781 |
| 6 | SRR10900583 | — | — | 0.778 |
| 7 | SRR8518410 | — | D | 0.776 |
| 8 | 3c5fe4dc-8606-4615-994f-c41861f08f5a | — | — | 0.775 |
| 9 | TCGA-05-4410-01A-21R-1858-07 | — | cohortA1 | 0.775 |
| 10 | SRR8518255 | — | D | 0.774 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.520 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.410 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.280 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.220 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.220 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.200 | Inavolisib | — uncovered |
| COMPLEMENT | 0.190 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.160 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.120 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.120 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.080 | Temsirolimus | — uncovered |
| MTORC1_SIGNALING | 0.070 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.060 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.060 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.030 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.010 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.010 | Idelalisib | — uncovered |